FDA sets new rules for a bleeding-detection capsule

The Food and Drug Administration has set formal rules for the ingestible gastrointestinal blood-detection capsule, giving manufacturers a clearer path to market. The final order takes effect June 17, 2026, and the prescription-only device stays prescription-only.

For patients and the clinicians who use diagnostic tools, the practical change is that FDA has now spelled out how this capsule fits into the system that governs it.

What class II means here

Class II sits in the middle of FDA’s device categories. It is reserved for products that need more oversight than basic devices, but not the most restrictive treatment, and the special controls are meant to provide reasonable assurance of safety and effectiveness.

FDA says that structure can help patients get access to beneficial innovative devices while also reducing regulatory burdens for manufacturers working through the approval path.

The date that anchors the rule

The agency also says the classification was applicable on February 24, 2023, even though the final order becomes effective now. That date matters to manufacturers because it marks the formal regulatory lane for the device type, and it matters to doctors and clinics because the capsule now has a clearer framework behind it as a diagnostic option.